EDITORIAL
2921
Indocyanine green-based fluorescence imaging in visceral and hepatobiliary and pancreatic surgery: State of the art and future directions
Baiocchi GL, Diana M, Boni L

REVIEW
2931
Perioperative thromboprophylaxis in liver transplant patients
De Pietri L, Montalti R, Nicolini D, Troisi RI, Mocchegiani F, Vivarelli M

2949
MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside
To KK, Tong CW, Wu M, Cho WC

2974
Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model"
Fang YL, Chen H, Wang CL, Liang L

MINIREVIEWS
2984
Role of aldehyde dehydrogenase 2 in ischemia reperfusion injury: An update

2995
Multiparametric analysis of colorectal cancer immune responses
Leman JK, Sandford SK, Rhodes JL, Kemp RA

ORIGINAL ARTICLE
Retrospective Study
3006
Push vs pull method for endoscopic ultrasound-guided fine needle aspiration of pancreatic head lesions: Propensity score matching analysis

3013
Liver intravoxel incoherent motion diffusion-weighted imaging for the assessment of hepatic steatosis and fibrosis in children

Clinical Trials Study
3021
New fecal test for non-invasive Helicobacter pylori detection: A diagnostic accuracy study

Observational Study
3030
Long-term outcomes of endoscopic resection for small (≤ 4.0 cm) gastric gastrointestinal stromal tumors originating from the muscularis propria layer
Zhang Y, Mao XL, Zhou XB, Yang H, Zhu LH, Chen G, Ye LP

SYSTEMATIC REVIEWS
3038
Systematic overview of hepatitis C infection in the Middle East and North Africa
Editorial board member of *World Journal of Gastroenterology*, C. Mel Wilcox, MD, Doctor, Professor, Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL 35294, United States

**AIMS AND SCOPE**

IWJG (World J Gastroenterol, *WJG*), print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 642 experts in gastroenterology and hepatology from 59 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreateology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

**INDEXING/ABSTRACTING**

*World Journal of Gastroenterology* (WJG) is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2018 edition of Journal Citation Reports® cites the 2017 impact factor for WJG as 3.300 (5-year impact factor: 3.387), ranking WJG as 35th among 80 journals in gastroenterology and hepatology (quartile in category Q2).

**EDITORS FOR THIS ISSUE**

- **Editorial Board members**
  - Responsible Assistant Editor: Xiang Li
  - Responsible Electronic Editor: Yan Huang
  - Proofing Editor-in-Chief: Lian-Sheng Ma

- **EDITORIAL OFFICE**
  - Ze-Mao Gong, Director
  - World Journal of Gastroenterology
  - Baishideng Publishing Group Inc
  - 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
  - Telephone: +1-925-2238242
  - Fax: +1-925-2238243
  - E-mail: editorialoffice@wjgnet.com
  - Help Desk: http://www.f6publishing.com/helpdesk
  - http://www.wjgnet.com

- **PUBLISHER**
  - Baishideng Publishing Group Inc
  - 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
  - Telephone: +1-925-2238242
  - Fax: +1-925-2238243
  - E-mail: bpgoffice@wjgnet.com
  - Help Desk: http://www.f6publishing.com/helpdesk
  - http://www.wjgnet.com

- **COPYRIGHT**
  © 2018 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

- **SPECIAL STATEMENT**
  All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

- **INSTRUCTIONS TO AUTHORS**
  Full instructions are available online at http://www.wjgnet.com/bpg/guidelines/204

- **ONLINE SUBMISSION**
  http://www.f6publishing.com
Role of aldehyde dehydrogenase 2 in ischemia reperfusion injury: An update

Arnau Panisello-Roselló, Alexandre Lopez, Emma Folch-Puy, Teresa Carbonell, Anabela Rolo, Carlos Palmeira, René Adam, Marc Net, Joan Roselló-Catafau

Abstract

Aldehyde dehydrogenase 2 (ALDH2) is best known for its critical detoxifying role in liver alcohol metabolism. However, ALDH2 dysfunction is also involved in a wide range of human pathophysiological situations and is associated with complications such as cardiovascular diseases, diabetes mellitus, neurodegenerative diseases and aging. A growing body of research has shown that ALDH2 provides important protection against oxidative stress and the subsequent loading of toxic aldehydes such as 4-hydroxy-2-nonenal and adducts that occur in human diseases, including ischemia reperfusion injury (IRI). There is increasing evidence of its role in IRI pathophysiology in organs such as heart, brain, small intestine and kidney; however, surprisingly few studies have been carried out in the liver, where ALDH2 is found in abundance. This study reviews the role of ALDH2 in modulating the pathways involved in the pathophysiology of IRI associated with oxidative stress and the subsequent loading of toxic aldehydes. Special emphasis is placed on the role of ALDH2 agonists such as Alda-1, which may become a useful therapeutic tool for preventing the deleterious effects of IRI in organ transplantation.

Key words: Aldehyde dehydrogenase 2; 4-hydroxy-2-nonenal; IRI; ALDH2; Alda-1; Therapeutic.
Aldehyde dehydrogenase 2 (ALDH2) plays a crucial role not only in liver ethanol metabolism but also in diverse pathophysiological dysfunctions including cardiovascular diseases, stroke, diabetes, neuro-degenerative dysfunctions, and aging. Its involvement has recently been identified in ischemia reperfusion injury (IRI). The present study provides an updated review of the literature on the role of ALDH2 in ischemia-reperfusion injury and its activation in different organs (heart, brain, kidney, intestine, etc) focusing especially on its possible use as a potential therapeutic target for preventing IRI associated with organ transplantation.

INTRODUCTION

Aldehyde dehydrogenase 2 (ALDH2), a tetrameric allosteric mitochondrial enzyme, is one of the 19 different ALDH enzymes ubiquitously expressed in all human tissues. It is most abundant in the liver, where it plays an essential role in the ethanol detoxifying pathway. This pathway comprises two enzymatic steps. In the first, ethanol is metabolized by alcohol dehydrogenase (ADH) to form acetaldehyde, which is highly diffusible and crosses biological membranes, then circulates in the blood and is metabolized by ALDH2 to acetic acid. ALDH2 is also responsible for the detoxification of other toxic short-term aldehydes, including some aromatic and polycyclic types. In addition, ALDH2 oxidizes endogenous aldehydic products from lipid peroxidation of mitochondrial and plasma membranes under oxidative stress conditions, such as 4-hydroxy-2-nonenal (4-HNE) and lipoperoxides (malondialdehyde, MDA). The specific electrophilic features of 4-HNE confer on this molecule a high reactivity and capacity to modify enzymes like kinases, belonging to sensitive pathways of cell homeostasis such as mitochondrial bioenergetics, redox balance, ROS formation, autophagy, apoptosis, and so on.

4-HNE has been shown to inflict damage in a wide variety of cell components, including some aromatic and polycyclic types. ALDH2 overexpression delays the formation of 4-HNE and toxic aldehyde adducts, and thus preserves the mitochondrial function during IRI. Nevertheless, despite the ability of ALDH2 to remove these aldehyde adducts, when 4-HNE is accumulated at high concentrations, it may act as an ALDH2 inhibitor in vitro, countering its beneficial effects and worsening the impact of I/R insult. 4-HNE has been shown to inflict organ damage in a wide variety of cell components, including cardiovascular diseases, stroke, diabetes, neuro-degenerative dysfunctions, and aging. Its involvement has recently been identified in ischemia reperfusion injury (IRI). The present study provides an updated review of the literature on the role of ALDH2 in ischemia-reperfusion injury and its activation in different organs (heart, brain, kidney, intestine, etc) focusing especially on its possible use as a potential therapeutic target for preventing IRI associated with organ transplantation.

Core tip: Aldehyde dehydrogenase 2 (ALDH2) plays a crucial role not only in liver ethanol metabolism but also in diverse pathophysiological dysfunctions including cardiovascular diseases, stroke, diabetes, neuro-degenerative dysfunctions, and aging. Its involvement has recently been identified in ischemia reperfusion injury (IRI). The present study provides an updated review of the literature on the role of ALDH2 in ischemia-reperfusion injury and its activation in different organs (heart, brain, kidney, intestine, etc) focusing especially on its possible use as a potential therapeutic target for preventing IRI associated with organ transplantation.
exposing the cell to a high level of stress and finally leading to its death. In this regard, it is clear that 4-HNE may modify essential cell-signaling molecules of survival mechanisms, as it does in autophagy (AMPK) and apoptosis (Akt) [27,28,30].

Ultimately, the clearance ratio of 4-HNE-adducts by ALDH2 and the ALDH2-4-HNE balance is crucial in order to prevent the modulation of survival mechanisms by 4-HNE and thus minimize some of the deleterious effects of IRI caused by the formation of these toxic aldehydes (Figure 1).

**ALDH2 AND AUTOPHAGY**

Autophagy is believed to play a key role in cell survival, with distinct functions depending on the event the cell is facing. In fact, autophagy is a cellular housekeeping mechanism, which in physiological conditions removes long-lived, aggregated and misfolded proteins, clears damaged organelles and plays an important role in the “survival and death” strategies of cellular stress responses, as occur in the I/R condition [31,32-34].

Autophagy has two paradoxically opposite behaviors, depending on the stage of the I/R condition: during ischemia, certain levels of autophagy are cytoprotective [36], but during reperfusion it is detrimental [35,37]. One of the key elements that regulate autophagy is the mammalian target of rapamycin (mTOR), an autophagy inhibitor. The inhibitory effect of mTOR over autophagy can be enhanced by Akt during reperfusion, or inhibited by AMPK (in both ischemia and reperfusion) [38]. Taking into account the dual behavior of autophagy and seeing some of its regulators, the role that ALDH2 plays in I/R is also dual: During ischemia, ALDH2 benefits AMPK activation, thus contributing to the inhibition of mTOR and subsequently increasing cytoprotective autophagy. On the other hand, during the reperfusion phase, cytoprotective autophagy is no longer active. Under reperfusion conditions, ALDH2 inhibits AMPK but also activates Akt, whose phosphorylation is kicked on to activate mTOR, thus resulting in a detrimental Akt-dependent inhibition of autophagy [28]. The ALDH2 dual regulatory effect on autophagy mechanisms through the Akt/AMPK/mTOR pathway could be a useful tool for preventing IRI. Considering that both AMPK and Akt are targets for 4-HNE, the beneficial effects that ALDH2 exerts on autophagy may be due both to its interaction with AMPK and to its capacity to remove 4-HNE (Figure 2).

We have seen that autophagy is a mechanism which, during periods of scarce resources, enables the cell to recycle its own products in order to survive. Most of this survival potential is performed through the preservation of the mitochondria, which are among the organelles most in need of protection. Therefore, mitophagy, the selective process to auto-phagocytize mitochondria, should be carefully regulated [36]. Some IRI-related studies report that after ALDH2 activation, the mitophagy regulators tensin homolog-induced putative kinase 1 (PINK1)/Parkin expression is suppressed, resulting in reduced injury. Even though the specific mechanism of action remains unclear (either via direct inhibition or via 4-HNE cleansing), ALDH2 clearly exerts a beneficial effect on mitophagy [27].

We can conclude that ALDH2 plays a positive role in the modulation of cyto-protective autophagy. It is an especially promising agent for the regulation of the deleterious effects of autophagy in cold IRI processes associated with organ transplantation.

**ALDH2: NECROPTOSIS AND APOPTOSIS**

Programmed cell death results in either a lytic or a non-lytic morphology, which includes different cell signaling pathways. It can be caused by well-known mechanisms such as autophagy, apoptosis, necrosis and necroptosis [28,29,30], which are determinant for organ preservation/cell survival associated with ischemia reperfusion injury.

Briefly, “necrosis” is one of the most frequent consequences of metabolic injury due to the organ oxygen deprivation during ischemia, leading to ATP depletion. It is characterized by cell swelling, membrane rupture and release of cell contents with the subsequent inflammatory response [40]. By contrast, “apoptosis” is a non-lytic form of silent programmed cell death in which the individual dying cells separate from their neighbors and shrink rather than swell [40]. Cell death by necrosis may also be programmed, as also occurs in apoptosis, and is then called “necroptosis”. In any case, distinct signaling events drive the lytic cell and non-lytic cell death processes (necroptosis and apoptosis, respectively). Thus, necroptosis is similar in nature to necrosis but it is induced by the activation of RIPK1 (receptor-interacting protein kinase 1) and RIPK3.
Recently, Zhong et al.\textsuperscript{45} reported that low ALDH2 promotes liver apoptosis through the MAPK pathway when ALDH2 agonists are used, in which ALDH2 action is not only based on the 4-HNE clearance ratio, but also on its subsidiary involvement in controlling indirect 4-HNE pathways. Again, the ratio of 4-HNE formation and its cleansing by ALDH2 is essential. High 4-HNE levels will limit ALDH2 activity, avoiding subsequent 4-HNE clearance and producing a positive 4-HNE feedback that ultimately causes apoptosis and cell death\textsuperscript{1,42} (Figure 3).

**ALDH2 ACTIVATION AND IRI PREVENTION IN DIFFERENT ORGANS: SOME CONSIDERATIONS**

In general, ALDH2 activation plays a protective role in the complex physiopathology of IRI, whose beneficial effects have mostly been studied in the heart, inducing cardio-protection as well as a protective role against the I/R insult\textsuperscript{12,46}. This protection has been evidenced in other organs such as brain, intestine, kidney and spinal cord\textsuperscript{16,20,22,24}. Surprisingly, the role of ALDH2 in hepatic I/R has not been studied in depth, even though the liver is one of the organs where ALDH2 is most abundant\textsuperscript{1}. This is probably due to the fact that most studies of ALDH2 in liver have focused on ethanol metabolism disorders.

In the following lines, we describe the most
important ongoing research into the role of ALDH2 in IRI in heart, brain, eyes, intestine, and kidney.

ALDH2 and heart

The most important feature of ALDH2 myocardial cardio-protection is the clearance of toxic aldehydes (such as 4-HNE) and its adducts \[\text{[12,46]}\]; Alda-1, an activator of ALDH2, raises this reactive aldehyde clearance even further, increasing the protection against myocardial IRI disorders \[\text{[14,15]}\]. Moreover, ALDH2 activation is associated with an improved mitochondrial function and a remodeling of the ventricular function \[\text{[47,48]}\]. ALDH2-induced cardio-protection (with the subsequent detoxification of toxic aldehydes) against IRI also occurs through a differential regulation of autophagy, involving both AMPK and Akt-mTOR signaling mechanisms, produced during ischemia and reperfusion respectively \[\text{[28,49]}\]. Guo et al \[\text{[50]}\] recently described a novel protective ALDH2 mechanism in type I diabetes, which defends against the induced myocardial dysfunction via an AMPK-dependent regulation of autophagy. These benefits are confirmed by the fact that ALDH2 inhibition by O-linked-N-acetylglucosamine (O-GlcNAC) acylation contributes to hyperglycemic exacerbation of myocardial IRI, which is prevented by Alda-1 \[\text{[51]}\]. Even more recently, it has been reported that ALDH2 induces cardio-protection through the regulation of mitophagy by suppressing tensin homolog-induced putative kinase 1 (PINK1)/Parkin expression, thus preventing the accumulation of 4-HNE and other toxic species \[\text{[37]}\].

ALDH2 in brain, intestine, kidney and eyes

The role of ALDH2 in other organs, such as brain, eyes, intestine, and kidney, has been poorly investigated. In brain and intestine, ALDH2 activation contributes to the clearance of the 4-HNE accumulation and MDA generation against IRI. Alda-1, an ALDH2 agonist, increases the 4-HNE adduct clearance, subsequently promoting protection against brain IRI and preventing the deleterious effects of apoptosis \[\text{[15,16]}\]. In kidney, after bilateral ischemia, ALDH2 activation is involved in the protection induced by ethanol at physiological levels \[\text{[23]}\]. Interestingly, an increased ALDH2 expression also has a protective effect, reducing renal cell apoptosis by inhibiting the MAPK pathway, after using hypothermic machine perfusion \[\text{[20]}\].

Recent investigations have shown the existence of ALDH2 expression in adult rat retinal tissues, which may be involved in the retina redox balance. However, its role in the regulatory lipoperoxidation mechanisms associated with retinal ischemia reperfusion injury needs to be investigated in depth \[\text{[52,53]}\].

ALDH2 ACTIVATION: ISCHEMIC PRECONDITIONING

Several therapeutic surgical and pharmacological strategies have been used to protect the organ against I/R insult. As an example, "ischemic preconditioning" (IPC) is based on the application of a previous transient ischemia and/or reperfusion that will prepare the organ prior to a sustained I/R. IPC was initially evidenced in the heart by Murry et al \[\text{[54]}\] but has also been found to be protective for other organs such as kidney, intestine and liver \[\text{[55-57]}\]. Another surgical strategy is "remote ischemic preconditioning" (RIPC) \[\text{[58]}\], which consists in the application of brief ischemia in one organ to confer protection on distant organs as well \[\text{[59]}\]. The involvement of ALDH2 as an important mediator in the benefits conferred by RIPC has also been discussed by Contractor et al \[\text{[59]}\].

ALDH2 ACTIVATION: PHARMACOLOGICAL PRECONDITIONING

The use of pharmacological agents to promote organ protection (pharmacological preconditioning) is limited when it is mandatory to avoid their potential undesirable secondary effects. We have assessed the protective role of ALDH2 when using different protective strategies against IRI based on the administration of volatile anesthetics (isoflurane), nitrites/nitrates and ALDH2 agonists (Alda-1).

ALDH2 and isoflurane preconditioning

Recent investigations in the heart and other organs have demonstrated that the use of isoflurane, a volatile anesthetic agent, is an effective preconditioning agent.
that mimics the protective effects of IPC but avoids some of its disadvantages caused by the reduction of the blood flow, and presents greater ethical acceptability and clinical safety\[^{60-62}\]. ALDH2 is involved in the cardio-protection induced by isoflurane preconditioning, and this ALDH2/isoflurane-induced cardio-protection is substantially blocked by a PKC\(\varepsilon\) inhibitor, suggesting that mitochondrial PKC\(\varepsilon\) plays an important role in isoflurane-induced protection mechanisms. It has been discussed whether the phosphorylation of ALDH2 increases PKC\(\varepsilon\) mitochondrial translocation, and the inhibition of mitochondrial translocation by other protein kinases such as PKC delta, contribute even more to isoflurane protection against I/R insult\[^{51}\].

**ALDH2 and ethanol preconditioning**

Ethanol, at low doses, also acts as a preconditioning agent\[^{51}\]. Its acute cardio-protective effects are critically modulated by the dose used and by whether it remains present during the ischemic period. In these conditions of ethanol preconditioning, ALDH2 is activated to induce protection against IRI through the mitochondrial translocation of PKC\(\varepsilon\), which is responsible for the increased metabolism from HNE to HNA, thus limiting the accumulation of HNE protein adducts and improving cardiac function\[^{64,65}\].

In this context, it has been suggested that the use of ALDH2 activators mimics ethanol cardio-protection. In addition, ALDH2 protection against ethanol toxicity is regulated by Akt and AMPK, and subsequently, autophagy and apoptosis through their downstream substrate mTOR\[^{28}\].

**ALDH2 and NO/nitrite preconditioning**

Nitric oxide (NO) is a free-radical gas, considered as a relevant therapeutic tar- get during IRI. Its effects on I/R injury are probably related to the dose or to the conditions during ischemia and reperfusion, usually at nanomolar or low micromolar concentrations\[^{66}\]. Apart from its role in tissue protection during ischemia, and due to its volatile nature, NO is a fast-response cell signaling molecule and a well-known vasodilator during hypoxic events, also regulating mitochondrial oxygen consumption\[^{66}\]. There is growing evidence that eNOS-derived NO is a critical component in IPC and APC signal transduction\[^{67,68}\]. Last but not least, due to its reductive capacity, NO is a potent ROS scavenger, and thus, performs one of the most important functions during reperfusion\[^{69}\].

As a volatile molecule, the half-life of NO is not very long; this is why there is a need for a pool of nitrogen in a more stable form, i.e., nitrates (NO\(\varepsilon\)-) and nitrates (NO\(\varepsilon\)-). Nitrates are the reduced form of nitrates, and under physiological conditions they can be recycled in blood and tissues, where NO generation from nitrates is linearly dependent on oxygen and pH levels\[^{66,69}\].

It has been widely shown that ALDH2 has a reductase-dependent activity that produces the bioconversion of nitroglycerin to 1, 2-glyceryl denigrates, resulting in the release of NO\[^{11}\]. Further experiments have shown that in vitro, ALDH2 is partially responsible for nitrite bioactivation, promoting vasodilation during hypoxic episodes (Figure 4). However, Oelze et al\[^{70}\] showed that the peroxynitrite generated from NO impairs the enzymatic activity of ALDH2, and therefore, the scavenging activity of NO may result in a suicide inhibition of ALDH2 in later stages.

The role of ALDH2 cannot be conclusively confirmed, due to the impossibility of ruling out other non-enzymatic or nitrite reductase species (e.g., eNOS)\[^{71-73}\]. However, it can be concluded that ALDH2 is closely related to NO and nitrogen metabolism and exerts positive effects\[^{72,73}\].

**ALDH2 agonist preconditioning: Alda-1**

With this in mind, it has been proposed that new therapeutic ALDH2 approaches might be based on promoting ALDH2 over-expression by using ALDH2 activators and determining the role of ALDH2 in a variety of human pathologies such as IRI. Here we focus specifically on the use of Alda-1, a selective ALDH2 agonist, in IRI in different organs.

Small molecules called ALDAs have been used as activators of ALDH2. One of the most frequently used is Alda-1. Defined as N-(1,3-benzodioxol-5-ylmethyl)-2,6 di-chloro-benzoamide, Alda-1 increases ALDH2 activity in humans twofold with its wild-type and 11-fold with its defective variant ALDH2\(^*\)2\[^{11}\].

Experiments have shown that the administration of Alda-1 just before the ischemic insult reduces infarct size by 60%, most likely through ALDH2 activation\[^{12}\]. Alda-1 also has beneficial effects on the heart and brain by inhibiting 4-HNE and related adducts\[^{15}\]. A potential therapeutic value of Alda-1 during the progression of post-myocardial infarction cardiomyopathy has also been suggested\[^{20}\]. Alda-1 may be useful for treating heart failure patients, since ALDH2 activation in heart failure restores mitochondrial function and improves ventricular function and remodeling\[^{46}\]. It was recently reported that ALDH2 activation regulates mitophagy by preventing 4-HNE, ROS and superoxide dismutase (SOD) accumulation\[^{17}\]. Along these lines, the recent investigations by Zhu et al\[^{20}\] have shown that Alda-1 pre-treatment reduces the intestinal injury induced by I/R in mice. Benefits were associated with the prevention of 4-HNE and MDA accumulation, suggesting a potential clinical application in the near future\[^{21}\].

**FUTURE PERSPECTIVES OF ALDH2 IN COLD ISCHEMIA REPERFUSION INJURY/ORGAN TRANSPLANTATION**

ROS play a major role in the progression of IRI, which is inherent to organ transplantation. ROS are responsible for the generation of MDA, as well as other toxic aldehydes
like 4-HNE and its adducts. During graft reperfusion, ROS are mainly produced in the mitochondria, becoming the main source of lipoperoxides and toxic aldehydes. Therefore, the prevention and clearance of those toxic elements generated during an episode of ischemia-reperfusion is decisive in organ transplantation, and the role of ALDH2 is crucial.

So far, the vast majority of investigations on the role of ALDH2 activation in organ preservation are limited to the heart and kidney\cite{22,72}. Gong et al\cite{72} demonstrated that addition of Alda-1 (ALDH2 activator) to histidine-ketoglutarate-tryptophan (HTK; a solution regularly used in heart surgery) improved cardio-protection through the subsequent ALDH2 activation and toxic aldehyde removal. The fact that Alda-1 ameliorates the quality of cardioplegic solutions such as HTK suggests that ALDH2 activators could be used to improve preservation solutions meant for other organs besides the heart, such as UW, HTK, Celsior and IGL-1, which are used for clinical transplantation in liver, where ALDH2 has an important presence\cite{75}.

These findings have a bearing on the consideration of the potential use of ALDH2 activators as additives in organ preservation solutions in order to improve their protective quality. They are also relevant to the assessment of the contribution of various commercial solutions to the preservation of mitochondrial ALDH2 activity during graft cold storage, especially when expanded criteria donors are used.

Recent studies have reported higher mitochondrial ALDH2 activity in liver grafts preserved in IGL-1 (24 h at 4 °C) than in livers preserved in UW or HTK solutions\cite{76}. These results are consistent with the increases reported in renal ALDH2 activity by Zhong et al\cite{22}, who subjected kidney grafts to machine perfusion preservation before transplantation.

These results confirm that ALDH2 plays a role in both static and dynamic graft preservation. It exerts a protective effect, during the ischemic phase by tackling ATP breakdown and during the reperfusion phase by reducing oxidative damage, which are inherent conditions of IRI. In this regard, further studies of ALDH2 using machine perfusion strategies in subnormothermic conditions should be carried out in order to improve the subsequent graft outcome.

Finally, although ALDH2 plays a role in distinct organs with well-defined physiological functions (heart, brain, eyes, liver, kidney and intestine), each organ contains multiple different cell types which, in turn, may give specific responses under ALDH2 activation/administration. Few studies have sought to clarify the relationship between ALDH2 and specific cell types or its influence on the substantial cross-talk between the different cells in each organ under ALDH2 administration\cite{77}. Therefore, further investigation of this issue is now warranted.

**CONCLUSION**

In recent years, the ability of ALDH2 to modify the activity of some key enzymes and essential survival pathways of the cell has been demonstrated (autophagy, apoptosis, necroptosis, etc). Some of its effects are exerted directly through its catalytic center, in a one-to-one interaction with those key enzymes that modifies the whole metabolic pathway. However, it may also regulate the metabolism indirectly, removing and cleansing toxic elements like 4-HNE and its adducts. During graft reperfusion, ROS are mainly produced in the mitochondria, becoming the main source of lipoperoxides and toxic aldehydes. Therefore, the prevention and clearance of those toxic elements generated during an episode of ischemia-reperfusion is decisive in organ transplantation, and the role of ALDH2 is crucial. So far, the vast majority of investigations on the role of ALDH2 activation in organ preservation are limited to the heart and kidney\cite{22,72}. Gong et al\cite{72} demonstrated that addition of Alda-1 (ALDH2 activator) to histidine-ketoglutarate-tryptophan (HTK; a solution regularly used in heart surgery) improved cardio-protection through the subsequent ALDH2 activation and toxic aldehyde removal. The fact that Alda-1 ameliorates the quality of cardioplegic solutions such as HTK suggests that ALDH2 activators could be used to improve preservation solutions meant for other organs besides the heart, such as UW, HTK, Celsior and IGL-1, which are used for clinical transplantation in liver, where ALDH2 has an important presence\cite{75}.

These findings have a bearing on the consideration of the potential use of ALDH2 activators as additives in organ preservation solutions in order to improve their protective quality. They are also relevant to the assessment of the contribution of various commercial solutions to the preservation of mitochondrial ALDH2 activity during graft cold storage, especially when expanded criteria donors are used.

Recent studies have reported higher mitochondrial ALDH2 activity in liver grafts preserved in IGL-1 (24 h at 4 °C) than in livers preserved in UW or HTK solutions\cite{76}. These results are consistent with the increases reported in renal ALDH2 activity by Zhong et al\cite{22}, who subjected kidney grafts to machine perfusion preservation before transplantation.

These results confirm that ALDH2 plays a role in both static and dynamic graft preservation. It exerts a protective effect, during the ischemic phase by tackling ATP breakdown and during the reperfusion phase by reducing oxidative damage, which are inherent conditions of IRI. In this regard, further studies of ALDH2 using machine perfusion strategies in subnormothermic conditions should be carried out in order to improve the subsequent graft outcome.

Finally, although ALDH2 plays a role in distinct organs with well-defined physiological functions (heart, brain, eyes, liver, kidney and intestine), each organ contains multiple different cell types which, in turn, may give specific responses under ALDH2 activation/administration. Few studies have sought to clarify the relationship between ALDH2 and specific cell types or its influence on the substantial cross-talk between the different cells in each organ under ALDH2 administration\cite{77}. Therefore, further investigation of this issue is now warranted.

**CONCLUSION**

In recent years, the ability of ALDH2 to modify the activity of some key enzymes and essential survival pathways of the cell has been demonstrated (autophagy, apoptosis, necroptosis, etc). Some of its effects are exerted directly through its catalytic center, in a one-to-one interaction with those key enzymes that modifies the whole metabolic pathway. However, it may also regulate the metabolism indirectly, removing and cleansing toxic...
sub-products resulting from pathologies like IRI, which compromise cell viability, as we have seen in the case of 4-HNE (Figure 5).

As a result, ALDH2 will affect any metabolic pathway in which 4-HNE is involved, and so its importance lies not only in its ability to activate other enzymes, but also in the collateral effects of those metabolic processes regulated by 4-HNE. In these processes, the regulation levels will depend on the balance of several factors such as the aldehyde/ALDH2 production ratio (where ALDH2 agonists take on a major role), the metabolization ratio of 4-HNE by ALDH2 and whether 4-HNE reaches the level of no-return where it inhibits all the ALDH2 present and the balance is definitely broken (Figure 5).

ALDH2 affects a wide range spectrum of mechanisms, among which ethanol metabolism has been the most studied. Yet, its role in important pathophysiological processes, such as IRI, remains unclear. With regard to IRI, the behavior of ALDH2 differs according to the phase (ischemia or reperfusion). Given that a variety of harmful elements such as 4-HNE are produced during an I/R episode, ALDH2 may play a critical role in the liver. This role should be further elucidated in future studies.

However, just as most studies have focused on the role of ALDH2 in ethanol metabolism rather than IRI, studies of ALDH2 in IRI are mainly focused on heart, brain or kidney and have paid hardly any attention to the liver. This is especially surprising in view of the fact that the liver is the organ with the highest ALDH2 concentration recorded so far due its detoxifying role. Just before this review was completed, a study evidencing the protective role of ALDH2 activation by Alda-1 in a model of warm ischemia reperfusion in liver was published.[78]

**ACKNOWLEDGMENTS**

This work was supported by Instituto de Salud Carlos III through FIS project PI 15/00110 co-funded by FEDER from Regional Development European Funds (European Union) and the FOIE GRAS project, which has received funding from the European Union’s Horizon 2020 Research and Innovation programme under the Marie Sklodowska-Curie Grant (Agreement No. 722619).

**REFERENCES**


16. Fu SH, Zhang HF, Yang ZB, Li TB, Liu B, Lou Z, Ma QL, Luo XJ,
Panisello-Roselló A et al. ALDH2 and ischemia reperfusion injury


Gao S, Andreeva K, Cooper NG. Ischemia-reperfusion injury of the retina is linked to necroptosis via the ERK1/2-RIP3 pathway. *Mot Vis 2014; 20: 1374-1387


Döll L. Pharmacological enrollment of aldehyde dehydrogenase modulators to assist treating ischemia reperfusion-induced intestinal injury: is there a gap to be bridged? *Clin Sci (Lond)* 2017; 131: 1137-1140 [PMID: 28533269 DOI: 10.1042/CS20170163]


Gomes KM, Campos JC, Bechara LR, Queliconi B, Lima VM, Disatnik MH, Magno P, Chen CH, Brum PC, Kowaltowski AJ,

Zhang Y, Ren J. Autophagy in ALDH2-elicited cardioprotection against ischemic heart disease: savior or slayer? *Autophagy* 2010; 6: 1212-1213.[PMID: 20935489]  


Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation* 1986; 74: 1124-1136.[PMID: 3769170 DOI: 10.1161/01.01.1986.1124]  


dehydrogenase 2 (ALDH2) in fatty liver graft protection mechanisms against cold ischemic injury. Poster session presented at: American Transplant Congress 2018; June 2-6; Seattle, Washington, USA


P- Reviewer: Abdel-Hamid SMM, Jin J, Katada K
S- Editor: Wang XJ
L- Editor: Filipodia
E- Editor: Huang Y